Ipsen falls after 'lower-quality' beat on Q4 sales, 2025 guidance

Ipsen SA

13/02/2025 08:26

** Shares in Ipsen  IPN.PA  edge down 2.6%, paring losses of
as much as 5%, after the French biopharma company reported its
Q4 and FY results  
    ** Jefferies says Q4 sales beat came with a lower-quality
beat on Somatuline offsetting misses from key growth drivers
Decapeptyl & Cabometyx, whilst Onivyde is in-line
    ** J.P. Morgan says the 3% Q4 Sales and 7% H2 core EBIT beat
was driven primarily by stronger Somatuline sales on continued
generic supply constraints, which more than offset the Dysport
miss and smaller misses across the portfolio, which could be a
source of disappointment
    ** The company also announced it expects for 2025 including
total sales growth greater than 5.0% at CER, and core operating
margin greater than 30.0% of total sales
    ** JPM says FY'25 guidance suggests consensus core operating
profit estimates could come down a couple pp, therefore it
expects the share to underperform by 1-2% 
    
  
($1 = 0.9590 euros)

 (Reporting by Marianna Ciabach-Malinowska)
 ((marianna.ciabach@tr.com))